| Literature DB >> 15531428 |
Mike Howsam1, Joan O Grimalt, Elisabet Guinó, Matilde Navarro, Juan Martí-Ragué, Miguel A Peinado, Gabriel Capellá, Victor Moreno.
Abstract
Organochlorine compounds have been linked to increased risk of several cancers. Despite reductions in their use and fugitive release, they remain one of the most important groups of persistent pollutants to which humans are exposed, primarily through dietary intake. We designed a case-control study to assess the risk of colorectal cancer with exposure to these chemicals, and their potential interactions with genetic alterations in the tumors. A subsample of cases (n = 132) and hospital controls (n = 76) was selected from a larger case-control study in Barcelona, Catalonia, Spain. We measured concentrations in serum of several organochlorines by gas chromatography. We assessed point mutations in K-ras and p53 genes in tissue samples by polymerase chain reaction/single-strand conformation polymorphism and assessed expression of p53 protein by immunohistochemical methods. An elevated risk of colorectal cancer was associated with higher serum concentrations of mono-ortho polychlorinated biphenyl (PCB) congeners 28 and 118. The odds ratio for these mono-ortho PCBs for middle and higher tertile were, respectively, 1.82 [95% confidence interval (CI), 0.90-3.70] and 2.94 (95% CI, 1.39-6.20). Alpha-hexachlorocyclohexane, hexachlorobenzene, and p,p'-DDE (4,4'-dichlorodiphenyltrichloroethene) showed nonsignificant increases in risk. Risk associated with mono-ortho PCBs was slightly higher for tumors with mutations in the p53 gene but was not modified by mutations in K-ras. Mono-ortho PCBs were further associated with transversion-type mutations in both genes. These results generate the hypothesis that exposure to mono-ortho PCBs contributes to human colorectal cancer development. The trend and magnitude of the association, as well as the observation of a molecular fingerprint in tumors, raise the possibility that this finding may be causal.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15531428 PMCID: PMC1247607 DOI: 10.1289/ehp.7143
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Population characteristics.
| Controls No. (%) | Cases No. (%) | OR (95% CI) | ||
|---|---|---|---|---|
| Sex | ||||
| Male | 43 (57) | 75 (57) | 1.00 | |
| Female | 33 (43) | 57 (43) | 1.07 (0.60–1.92) | |
| Age (years) | ||||
| 24–63 | 26 (34) | 46 (35) | 1.00 | |
| 63–73 | 25 (33) | 47 (36) | 1.09 (0.54–2.20) | |
| 73–92 | 25 (33) | 39 (30) | 0.91 (0.45–1.83) | |
| Energy intake (calories/day) | ||||
| 663–1,733 | 24 (32) | 46 (35) | 1.00 | |
| 1,733–2,280 | 26 (34) | 43 (33) | 0.82 (0.39–1.73) | |
| 2,280–4,418 | 26 (34) | 43 (33) | 0.83 (0.38–1.82) | |
| BMI | ||||
| 16.8–25.0 | 24 (32) | 56 (42) | 1.00 | 0.09 |
| 25.0–30.0 | 33 (43) | 51 (39) | 0.65 (0.34–1.25) | |
| 30.0–40.7 | 19 (25) | 25 (19) | 0.53 (0.24–1.17) | |
| BMI 10 years before diagnosis | ||||
| 17.6–25.0 | 19 (25) | 42 (32) | 1.00 | 0.79 |
| 25.0–30.0 | 42 (55) | 57 (43) | 0.61 (0.31–1.20) | |
| 30.0–43.1 | 15 (20) | 33 (25) | 0.95 (0.41–2.18) | |
| Plasma lipids (g/L) | ||||
| 2.58–4.94 | 26 (34) | 44 (33) | 1.00 | 0.49 |
| 4.94–5.85 | 21 (28) | 48 (36) | 1.37 (0.67–2.81) | |
| 5.85–9.55 | 29 (38) | 40 (30) | 0.79 (0.39–1.57) | |
| Alcohol duration (years) | ||||
| 0 | 34 (45) | 42 (32) | 1.00 | 0.05 |
| 1–40 | 19 (25) | 38 (29) | 2.22 (0.93–5.30) | |
| 40–74 | 23 (30) | 52 (39) | 2.40 (1.02–5.63) | |
| Alcohol consumption (g/day) | ||||
| 0 | 36 (47) | 42 (31) | 1.00 | 0.001 |
| 1–60 | 35 (46) | 66 (50) | 2.42 (1.13–5.17) | |
| 60–410 | 5 (6) | 24 (18) | 7.39 (2.13–25.7) | |
| Tobacco use (men | ||||
| Nonsmoker | 9 (20) | 20 (26) | 1.00 | 0.47 |
| Ex-smoker | 23 (53) | 37 (49) | 0.75 (0.29–2.00) | |
| Smoker | 11 (25) | 18 (24) | 0.66 (0.21–2.12) | |
| Smoking duration (years, men | ||||
| 0 | 9 (21) | 20 (27) | 1.00 | 0.81 |
| 1–40 | 20 (47) | 22 (29) | 0.48 (0.17–1.36) | |
| 40–79 | 14 (33) | 33 (44) | 1.05 (0.38–2.96) | |
| Parity (women) | ||||
| 0–2 | 6 (18) | 16 (28) | 1.00 | 0.78 |
| 2–4 | 20 (61) | 25 (44) | 0.55 (0.17–1.76) | |
| 4–9 | 7 (21) | 16 (28) | 1.25 (0.31–5.11) | |
| NSAID use | ||||
| None | 52 (68) | 101 (76) | 1.00 | 0.12 |
| Aspirin | 12 (15) | 22 (16) | 0.92 (0.42–2.04) | |
| Other | 12 (15) | 9 (6) | 0.43 (0.16–1.11) | |
Test for linear trend adjusted for age, sex, energy intake, and BMI.
Only 6% of women ever smoked in this population.
Lipid-corrected serum concentrations of OCs.
| OC | Median | LOD | Percent of samples > LOD |
|---|---|---|---|
| 3,686 (2,574–5,565) | 0.2 | 100 | |
| 444 (336–740) | 1.5 | 100 | |
| HCB | 1,753 (1,344–2,522) | 77.9 | 98 |
| α-HCH | 17 (< 2.8–30) | 2.8 | 61 |
| β-HCH | 1,057 (779–1,422) | 34.4 | 100 |
| γ-HCH | 10 (< 1.5–46) | 1.5 | 56 |
| PCB-28 | < 3.5 (< 3.5) | 3.5 | 25 |
| PCB-118 | 92 (< 21.0–127) | 21.0 | 62 |
| PCB-52 | < 4.6 (< 4.6) | 4.6 | 9 |
| PCB-153 | 362 (255–487) | 16.0 | 100 |
| PCB-138 | 308 (245–404) | 15.3 | 98 |
| PCB-180 | 252 (190–333) | 16.0 | 98 |
Lipid-corrected concentrations expressed as ng/g lipid.
Cutpoints were 33rd and 66th percentiles, except for compounds for which the 33rd percentile was < LOD, in which case median of measured values were used.
Lipid corrected (ng/g lipid) using average lipid concentration in the population (5.44 g lipid/L serum).
Proportion of samples with values > LOD.
Lipid-corrected serum concentrations [median (5th–95th percentile); ng/g lipid] of OCs in cases and controls.
| OC | Cases | Controls |
|---|---|---|
| 3,936 (600–11,804) | 2,977 (611–13,608) | |
| 396 (124–2,077) | 609 (137–3,848) | |
| HCB | 1,753 (487–5,777) | 1,763 (720–4,848) |
| α-HCH | 21 (< 2.8–94) | 14 (< 2.8–55) |
| β-HCH | 1,042 (315–2,971) | 1,119 (345–3,654) |
| γ-HCH | 10 (< 1.5–121) | 10 (< 1.5–399) |
| PCB-28 | < 3.5 (< 3.5–228) | < 3.5 (< 3.5–43) |
| PCB-118 | 103 (< 21–319) | 63 (< 21–404) |
| PCB-52 | < 4.6 (< 4.6–49) | < 4.6 (< 4.6–< 4.6) |
| PCB-153 | 381 (118–1,018) | 340 (118–917) |
| PCB-138 | 327 (121–992) | 301 (91–830) |
| PCB-180 | 259 (87–741) | 238 (72–650) |
Risk of colorectal cancer associated with organochlorine body burden.
| Controls No. (%) | Cases No. (%) | OR (95% CI) | ||
|---|---|---|---|---|
| Low | 31 (41) | 38 (29) | 1.00 | 0.19 |
| Medium | 21 (28) | 49 (37) | 2.17 (1.03–4.54) | |
| High | 24 (32) | 45 (34) | 1.60 (0.79–3.25) | |
| Low | 25 (33) | 44 (33) | 1.00 | 0.12 |
| Medium | 18 (24) | 52 (39) | 1.58 (0.74–3.36) | |
| High | 33 (43) | 36 (27) | 0.56 (0.27–1.17) | |
| HCB | ||||
| Low | 29 (38) | 40 (30) | 1.00 | 0.23 |
| Medium | 22 (29) | 47 (36) | 1.72 (0.83–3.54) | |
| High | 25 (33) | 45 (34) | 1.60 (0.62–4.15) | |
| α-HCH | ||||
| Low | 33 (43) | 48 (36) | 1.00 | 0.081 |
| Medium | 27 (36) | 37 (28) | 0.99 (0.49–1.98) | |
| High | 16 (21) | 47 (36) | 2.02 (0.95–4.29) | |
| β-HCH | ||||
| Low | 26 (34) | 44 (33) | 1.00 | 0.81 |
| Medium | 23 (30) | 45 (34) | 1.14 (0.55–2.36) | |
| High | 27 (36) | 43 (33) | 0.88 (0.39–2.02) | |
| γ-HCH | ||||
| < LOD | 30 (39) | 61 (46) | 1.00 | 0.28 |
| Medium | 22 (29) | 36 (27) | 0.79 (0.38–1.61) | |
| High | 24 (32) | 35 (27) | 0.69 (0.34–1.38) | |
| PCB-28 | ||||
| < LOD | 65 (86) | 91 (69) | 1.00 | 0.006 |
| > LOD | 11 (14) | 41 (31) | 2.75 (1.29–5.83) | |
| PCB-118 | ||||
| < LOD | 36 (47) | 43 (33) | 1.00 | 0.045 |
| Medium | 20 (26) | 39 (30) | 1.63 (0.80–3.31) | |
| High | 20 (26) | 50 (38) | 2.02 (1.00–4.08) | |
| PCB-52 | ||||
| < LOD | 69 (91) | 120 (91) | 1.00 | 0.77 |
| > LOD | 7 (9) | 12 (9) | 1.16 (0.42–3.19) | |
| PCB-153 | ||||
| Low | 30 (39) | 39 (30) | 1.00 | 0.57 |
| Medium | 22 (29) | 48 (36) | 1.50 (0.74–3.07) | |
| High | 24 (32) | 45 (34) | 1.22 (0.59–2.52) | |
| PCB-138 | ||||
| Low | 26 (34) | 43 (33) | 1.00 | 0.79 |
| Medium | 26 (34) | 44 (33) | 0.85 (0.41–1.75) | |
| High | 24 (32) | 45 (34) | 0.90 (0.43–1.90) | |
| PCB-180 | ||||
| Low | 29 (38) | 41 (31) | 1.00 | 0.63 |
| Medium | 24 (32) | 44 (33) | 1.20 (0.59–2.42) | |
| High | 23 (30) | 47 (36) | 1.19 (0.57–2.49) | |
p-Value for trend adjusted for age, sex, energy intake, and BMI.
Colorectal cancer risk for selected organochlorines in relation to K-ras and p53 mutations.
| Wild-type
| Mutated
| ||||
|---|---|---|---|---|---|
| No. (%) | OR (95% CI) | No. (%) | OR (95% CI) | ||
| K- | |||||
| | |||||
| Low | 16 (20) | 1.00 | 22 (44) | 1.00 | 0.012 |
| Medium | 34 (41) | 3.51 (1.49–8.24) | 15 (30) | 1.07 (0.42–2.72) | |
| High | 32 (39) | 2.78 (1.21–6.35) | 13 (26) | 0.72 (0.29–1.81) | |
| α-HCH | |||||
| Low | 28 (34) | 1.00 | 20 (40) | 1.00 | 0.55 |
| Medium | 27 (33) | 1.22 (0.57–2.61) | 10 (20) | 0.64 (0.25–1.66) | |
| High | 27 (33) | 2.16 (0.94–4.97) | 20 (40) | 1.75 (0.70–4.37) | |
| PCB-28 | |||||
| < LOD | 56 (68) | 1.00 | 35 (70) | 1.00 | 0.88 |
| > LOD | 26 (32) | 2.78 (1.24–6.25) | 15 (30) | 2.83 (1.13–7.06) | |
| PCB-118 | |||||
| < LOD | 26 (32) | 1.00 | 17 (34) | 1.00 | 0.42 |
| Medium | 25 (30) | 1.78 (0.81–3.90) | 14 (28) | 1.35 (0.53–3.43) | |
| High | 31 (38) | 2.27 (1.04–4.96) | 19 (38) | 1.64 (0.67–4.01) | |
| | |||||
| Low | 12 (31) | 1.00 | 11 (19) | 1.00 | 0.047 |
| Medium | 16 (41) | 2.24 (0.81–6.16) | 20 (34) | 2.94 (1.11–7.76) | |
| High | 11 (28) | 1.09 (0.39–3.05) | 28 (47) | 3.44 (1.39–8.47) | |
| α-HCH | |||||
| Low | 18 (46) | 1.00 | 16 (27) | 1.00 | 0.045 |
| Medium | 10 (26) | 0.76 (0.29–2.01) | 17 (29) | 1.39 (0.58–3.35) | |
| High | 11 (28) | 1.22 (0.44–3.34) | 26 (44) | 3.44 (1.40–8.45) | |
| PCB-28 | |||||
| < LOD | 29 (74) | 1.00 | 44 (75) | 1.00 | 0.98 |
| > LOD | 10 (26) | 2.16 (0.79–5.91) | 15 (25) | 2.06 (0.85–5.01) | |
| PCB-118 | |||||
| < LOD | 14 (36) | 1.00 | 18 (31) | 1.00 | 0.19 |
| Medium | 13 (33) | 1.72 (0.65–4.53) | 13 (22) | 1.31 (0.53–3.26) | |
| High | 12 (31) | 1.40 (0.52–3.75) | 28 (47) | 2.79 (1.22–6.37) | |
p-Value for interaction between OC and the genetic alteration adjusted for age, sex, energy intake, and BMI; tests for differences in the OR between wild-type and mutated cases.
Colorectal cancer risk for PCB-118 in relation to K-ras and p53 mutation type.
| Transitions | Transversions | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No. (%) | OR (95% CI) | No. (%) | OR (95% CI) | ||||||
| PCB-118 | |||||||||
| < LOD | 20 (37) | 1.00 | 6 (18) | 1.00 | 0.071 | ||||
| Medium | 17 (32) | 1.09 (0.28–4.28) | 12 (35) | 3.29 (0.66–16.4) | |||||
| High | 17 (32) | 1.93 (0.41–9.09) | 16 (47) | 6.52 (1.16–36.6) | |||||
| Trend test | 0.42 | 0.038 | |||||||
Mutations in K-ras and p53 classified as transitions (G:C→A:T) or transversions (G:C→T:A).
p-Value for interaction between PCB-118 and the mutation type; tests for differences in the OR between transitions and transversions.
Trend test p-value for the specific mutation type adjusted for age, sex, energy intake, and BMI.